The Anti-diabetic Drug Gliquidone Modulates Lipopolysaccharide-Mediated Microglial Neuroinflammatory Responses by Inhibiting the NLRP3 Inflammasome

The sulfonylurea drug gliquidone is FDA approved for the treatment of type 2 diabetes. Binding of gliquidone to ATP-sensitive potassium channels (SUR1, Kir6 subunit) in pancreatic β-cells increases insulin release to regulate blood glucose levels. Diabetes has been associated with increased levels o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jieun, Park, Jin-Hee, Shah, Keshvi, Mitchell, Scott John, Cho, Kwangwook, Hoe, Hyang-Sook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Aging Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587901/
https://www.ncbi.nlm.nih.gov/pubmed/34776934
http://dx.doi.org/10.3389/fnagi.2021.754123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587901/
https://www.ncbi.nlm.nih.gov/pubmed/34776934
http://dx.doi.org/10.3389/fnagi.2021.754123

Ejemplares similares